Category News

U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved a new indication for PREVYMIS® (letermovir) for…

Read MoreU.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Canadian Cancer Trials Group (CCTG) today announced results from the Phase 3 CCTG IND.227/KEYNOTE-483 trial…

Read MoreKEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma

FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

AstraZeneca and Merck (NYSE: MRK),known as MSD outside of the United States and Canada, today announced that LYNPARZA in combination with abiraterone and prednisone or prednisolone (abi/pred) has been approved…

Read MoreFDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Aetna provides Morehouse School of Medicine with $140,000 community investment to advance health equity in Georgia

Aetna Better Health® of Georgia, a CVS Health® company (NYSE: CVS), announced that Aetna® provided a community investment of $140,000 to the Morehouse School of Medicine. The investment will support Morehouse…

Read MoreAetna provides Morehouse School of Medicine with $140,000 community investment to advance health equity in Georgia

CVS Health opens new Workforce Innovation and Talent Center within Goodwill of Greater Detroit

 CVS Health announced the opening of its newest Workforce Innovation and Talent Center (WITC) in collaboration with Goodwill Industries of Greater Detroit, offering comprehensive skills training, job placement and community health services. The innovation…

Read MoreCVS Health opens new Workforce Innovation and Talent Center within Goodwill of Greater Detroit

Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer

A McKesson business dedicated to leveraging oncology real-world evidence (RWE), clinical education, and provider technology to transform the fight against cancer, presented new data at the American Society of Clinical Oncology (ASCO) Annual Meeting…

Read MoreResearch Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different Patient Populations with Triple-Negative Breast Cancer

Cardinal Health launches Modern Commerce Solutions for Retail Independent Pharmacies powered by Square

Cardinal Health (NYSE: CAH) today launched modern payment solutions, powered by Square, to help independent pharmacies increase operational efficiency, stay current with customer payment preferences, and access integrated software tools for their business.…

Read MoreCardinal Health launches Modern Commerce Solutions for Retail Independent Pharmacies powered by Square

Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options

fizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 program comprising the REVISIT (NCT03329092) and ASSEMBLE (NCT03580044) studies evaluating the efficacy, safety, and tolerability of the novel…

Read MorePhase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options